The findings of Ricaurte (published in the same issue) are described, along with comments from several researchers, including A. Parrott and J. Cole. Acute and sub-acute effects of MDMA are well described, though the link between sub-acute effects and pharmacological effects suggested by the author is not supported in the literature. Ricaurte again states that his findings suggest that ecstasy users may be at risk for developing Parkinson's disease, but that this will only be apparent after 80% of dopamine (DA) neurons are damaged. However, given the high rates of damage seen in the monkeys and baboons in his study, it would seem that many ecstasy users should have reached or exceeded an 80% reduction in DA function if the doses Ricaurte used are equivalent to doses commonly self-administered in humans. The issue of dose equivalence between this study and those used by humans is not questioned in this report. Parrott claims that even novice ecstasy users exhibit tremor and twitches that can be explained via reduced DA function, without indicating the source of this information, whether it refers to acute, sub-acute or long-term effects and whether psychomotor skills were formally measured. Some indication is given that these findings are contested and that some psychologists wish to investigate the therapeutic uses of MDMA. However, it is never explicitly stated the proposed research into the therapeutic effects of MDMA will employ a dose regimen substantially different from that used in the studies of Ricaurte. The editorial piece accurately describes findings reported in the Ricaurte paper and notes skepticism concerning those findings, but overstates the ease of interspecies generalization.